AEON Biopharma Advances Biosimilar Program and Debt Reduction

AEON Biopharma ( (AEON) ) just unveiled an announcement.

On January 21, 2026, AEON Biopharma reported that it had held its scheduled Biosimilar Product Development Type 2a meeting with the U.S. Food and Drug Administration regarding ABP-450, an important procedural step expected to guide the next phase of its biosimilar development program once official meeting minutes are received. That same day, shareholders approved a series of November 2025 financing and capital-structure proposals, enabling the exchange of up to $15 million of Daewoong-held senior secured convertible notes into equity and new securities, substantially reducing AEON’s outstanding debt, simplifying its capital structure, and paving the way for a second closing of its private placement financing expected in the week of January 26, 2026, leaving the company better positioned to fund operations and advance its biosimilar strategy.

The most recent analyst rating on (AEON) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on AEON Biopharma stock, see the AEON Stock Forecast page.

Spark’s Take on AEON Stock

According to Spark, TipRanks’ AI Analyst, AEON is a Neutral.

The score is held down primarily by weak financial fundamentals—limited/absent revenue, persistent cash burn, and negative equity that increases funding and solvency risk. Offsetting this, technical indicators show moderate positive momentum with price above key moving averages and a positive MACD. Valuation appears low on P/E, but its usefulness is constrained by volatile/limited earnings and lack of dividend support.

To see Spark’s full report on AEON stock, click here.

More about AEON Biopharma

AEON Biopharma is a biopharmaceutical company focused on gaining accelerated and full-label access to the U.S. therapeutic neurotoxin market, which exceeds $3 billion annually, by developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX (onabotulinumtoxinA). Its lead asset, ABP-450, is the same botulinum toxin complex marketed cosmetically as Jeuveau by Evolus and is manufactured by Daewoong Pharmaceutical under cGMP in an FDA-, Health Canada-, and EMA-approved facility; the product is already approved as a biosimilar in India, Mexico, and the Philippines, and AEON holds exclusive rights for therapeutic indications in the U.S., Canada, the EU, the U.K., and select other territories.

Average Trading Volume: 217,987

Technical Sentiment Signal: Sell

Current Market Cap: $13.8M

See more data about AEON stock on TipRanks’ Stock Analysis page.